세계의 환자 리스크 계층화 시장 보고서(2025년)
Patient Risk Stratification Global Market Report 2025
상품코드 : 1717269
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

환자 리스크 계층화 시장 규모는 향후 수년간 비약적인 성장이 예상될 예정입니다. 예측 기간 동안의 성장은 중산층과 건강보험의 확대, 만성 질환의 유병률 증가, 예측 분석의 채택 증가, 건강의 사회적 결정 요인(SDOH)에 대한 관심 증가, 기술의 광범위한 활용에 의해 주도될 것으로 예상됩니다.

만성질환의 부담 증가가 환자 리스크 계층화 시장의 성장을 견인할 것으로 예측됩니다. 만성질환은 보통 3개월 이상 지속되는 장기적인 건강상태입니다. 환자 리스크 계층화는 만성 질환의 다양한 위험 수준에 있는 개인을 확인하고, 개별화 케어, 조기 개입, 보다 좋은 자원 관리, 건강 결과의 개선을 가능하게 합니다. 예를 들어, 2023년 1월 미국 국립생명공학정보센터(NCBI)는 만성 질환을 하나 이상 앓고 있는 50세 이상 인구가 2020년 7,150만 명에서 2050년에는 1억 4,270만 명으로 99.5% 증가할 것으로 예상한 바 있습니다. 또한 세계보건기구(WHO)는 2022년 9월 만성 질환이 전 세계 사망의 74%를 차지했으며, 이는 연간 4,100만 명이 사망하는 것과 같다고 강조했습니다. 심혈관 질환으로 1,790만 명이 사망하고, 암으로 930만 명, 만성 호흡기 질환으로 410만 명, 당뇨병으로 200만 명이 사망합니다. 결과적으로 만성 질환의 유병률 증가는 환자 리스크 계층화 시장의 주요 동인입니다.

환자 리스크 계층화 시장의 기업은 보다 정확한 리스크 평가와 맞춤 치료 계획을 제공함으로써 조기 발견과 환자의 결과를 개선하고 의료비를 절감하기 위해 질병 스크리닝에서 인공지능(AI) 등의 의료 기술을 추진하고 있습니다. 질병 검진 분야의 AI는 정교한 알고리즘과 머신러닝을 사용하여 의료 데이터를 분석함으로써 질병의 조기 발견을 촉진하고 대규모 데이터 세트를 신속하게 처리하여 진단 정확도를 향상시킵니다. 예를 들어, 2024년 5월 캐나다의 의료 서비스 회사인 WELL Health Technologies Corporation은 투자 회사인 HEALWELL AI와 함께 WELL AI Decision Support(WAIDS)를 출시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Patient risk stratification involves evaluating and classifying patients based on their likelihood of experiencing adverse health events. This process helps identify high-risk individuals for targeted interventions, optimize the use of resources, promote preventive care, improve care coordination, enhance patient outcomes, reduce costs, and aid in managing population health.

The primary types of patient risk stratification include predictive, retrospective, prospective, and concurrent models. Predictive risk stratification models analyze historical and current patient data to predict future health outcomes and identify those at high risk of developing particular conditions or complications. These models consist of software and services, with delivery options available both on-premise and via the cloud. Key applications include risk adjustment, clinical workflows, revenue cycle management, among others, and they are utilized by various end users, including healthcare providers, payers, and others.

The patient risk stratification market research report is one of a series of new reports from The Business Research Company that provides patient risk stratification market statistics, including patient risk stratification industry global market size, regional shares, competitors with a patient risk stratification market share, detailed patient risk stratification market segments, market trends and opportunities, and any further data you may need to thrive in the patient risk stratification industry. This patient risk stratification market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The patient risk stratification market size has grown exponentially in recent years. It will grow from $2.15 billion in 2024 to $2.82 billion in 2025 at a compound annual growth rate (CAGR) of 31.3%. The growth during the historical period can be attributed to the growing adoption of digitization, increased health risks, an aging population, a rise in medical errors, and the widespread use of electronic health records (EHR).

The patient risk stratification market size is expected to see exponential growth in the next few years. It will grow to $8.30 billion in 2029 at a compound annual growth rate (CAGR) of 31.0%. Looking ahead, growth during the forecast period is expected to be driven by the expanding middle class and health insurance coverage, the increasing prevalence of chronic diseases, the rising adoption of predictive analytics, a greater focus on social determinants of health (SDOH), and the broader use of technology. Key trends in the forecast period include advancements in analytics, artificial intelligence (AI), machine learning, healthcare technological innovations, wearable technology, and remote monitoring.

The increasing burden of chronic diseases is expected to drive the growth of the patient risk stratification market. Chronic diseases are long-term health conditions that typically last for three months or longer. The rise in chronic diseases can be attributed to several factors, including an aging population, unhealthy lifestyles, urbanization, environmental factors, limited access to healthcare, economic disparities, and elevated stress levels. Patient risk stratification helps identify individuals at varying risk levels for chronic diseases, enabling personalized care, early intervention, better resource management, and improved health outcomes. For example, in January 2023, the National Center for Biotechnology Information (NCBI) projected that the number of individuals aged 50 and older with at least one chronic illness will increase by 99.5%, from 71.5 million in 2020 to 142.7 million by 2050. Additionally, the World Health Organization (WHO) highlighted in September 2022 that chronic diseases are responsible for 74% of all deaths globally, equating to 41 million deaths annually. Cardiovascular diseases account for 17.9 million deaths, cancer causes 9.3 million, chronic respiratory diseases lead to 4.1 million deaths, and diabetes results in 2 million deaths. Consequently, the rising prevalence of chronic diseases is a major driver of the patient risk stratification market.

Companies in the patient risk stratification market are advancing healthcare technologies, such as artificial intelligence (AI) in disease screening, to improve early detection, patient outcomes, and reduce healthcare costs by providing more accurate risk assessments and personalized treatment plans. AI in disease screening employs sophisticated algorithms and machine learning to analyze medical data, facilitating early disease detection and improving diagnostic accuracy by quickly processing large datasets. For example, in May 2024, WELL Health Technologies Corporation, a Canadian healthcare company, alongside its investee company HEALWELL AI, launched WELL AI Decision Support (WAIDS). This tool focuses on rare diseases and chronic conditions such as kidney disease, hypertension, and diabetes, offering risk stratification and helping clinicians identify care gaps and actionable data at the point of care.

In December 2023, Healthcare Outcomes Performance Company (HOPCo), a US-based provider specializing in healthcare performance improvement solutions, acquired MyACTome, a US-based company that offers a smartphone platform for assessing fall risk and frailty. This acquisition is aimed at improving patient outcomes and enhancing healthcare efficiency, particularly in patient risk stratification.

Major players in the patient risk stratification market are Bristol-Myers Squibb, Thermo Fisher Scientific Inc., Abbott Laboratories, Sales Force Inc., Medtronic plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Adobe Inc., Persistent Systems, NextGen Healthcare Inc., Health Catalyst, Freenome, Strive Health, Medeanalytics Inc., American Academy of Family Physicians, Lightbeam Health Solutions, Graphnet Health Ltd., Innova Medical Group Inc., Equipo Health Inc., Epic Systems Corporation

North America was the largest region in the patient risk stratification market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in patient risk stratification report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the patient risk stratification market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The patient risk stratification market includes revenues earned by entities by risk assessment and stratification services, telehealth services, medication management services, chronic disease risk assessment services, and genomic risk stratification services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Patient Risk Stratification Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on patient risk stratification market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for patient risk stratification ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The patient risk stratification market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Patient Risk Stratification Market Characteristics

3. Patient Risk Stratification Market Trends And Strategies

4. Patient Risk Stratification Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Patient Risk Stratification Growth Analysis And Strategic Analysis Framework

6. Patient Risk Stratification Market Segmentation

7. Patient Risk Stratification Market Regional And Country Analysis

8. Asia-Pacific Patient Risk Stratification Market

9. China Patient Risk Stratification Market

10. India Patient Risk Stratification Market

11. Japan Patient Risk Stratification Market

12. Australia Patient Risk Stratification Market

13. Indonesia Patient Risk Stratification Market

14. South Korea Patient Risk Stratification Market

15. Western Europe Patient Risk Stratification Market

16. UK Patient Risk Stratification Market

17. Germany Patient Risk Stratification Market

18. France Patient Risk Stratification Market

19. Italy Patient Risk Stratification Market

20. Spain Patient Risk Stratification Market

21. Eastern Europe Patient Risk Stratification Market

22. Russia Patient Risk Stratification Market

23. North America Patient Risk Stratification Market

24. USA Patient Risk Stratification Market

25. Canada Patient Risk Stratification Market

26. South America Patient Risk Stratification Market

27. Brazil Patient Risk Stratification Market

28. Middle East Patient Risk Stratification Market

29. Africa Patient Risk Stratification Market

30. Patient Risk Stratification Market Competitive Landscape And Company Profiles

31. Patient Risk Stratification Market Other Major And Innovative Companies

32. Global Patient Risk Stratification Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Patient Risk Stratification Market

34. Recent Developments In The Patient Risk Stratification Market

35. Patient Risk Stratification Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기